JP2022533983A5 - - Google Patents

Info

Publication number
JP2022533983A5
JP2022533983A5 JP2021568813A JP2021568813A JP2022533983A5 JP 2022533983 A5 JP2022533983 A5 JP 2022533983A5 JP 2021568813 A JP2021568813 A JP 2021568813A JP 2021568813 A JP2021568813 A JP 2021568813A JP 2022533983 A5 JP2022533983 A5 JP 2022533983A5
Authority
JP
Japan
Prior art keywords
disease
gene therapy
delivery
composition according
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021568813A
Other languages
English (en)
Japanese (ja)
Other versions
JP7707081B2 (ja
JP2022533983A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/028352 external-priority patent/WO2020236352A1/en
Publication of JP2022533983A publication Critical patent/JP2022533983A/ja
Publication of JP2022533983A5 publication Critical patent/JP2022533983A5/ja
Application granted granted Critical
Publication of JP7707081B2 publication Critical patent/JP7707081B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021568813A 2019-05-17 2020-04-15 網膜細胞を標的とした最適化された遺伝子治療 Active JP7707081B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962849794P 2019-05-17 2019-05-17
US62/849,794 2019-05-17
PCT/US2020/028352 WO2020236352A1 (en) 2019-05-17 2020-04-15 Optimized gene therapy targeting retinal cells

Publications (3)

Publication Number Publication Date
JP2022533983A JP2022533983A (ja) 2022-07-27
JP2022533983A5 true JP2022533983A5 (cg-RX-API-DMAC7.html) 2023-04-25
JP7707081B2 JP7707081B2 (ja) 2025-07-14

Family

ID=70482910

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021568813A Active JP7707081B2 (ja) 2019-05-17 2020-04-15 網膜細胞を標的とした最適化された遺伝子治療
JP2021568543A Pending JP2022533645A (ja) 2019-05-17 2020-04-15 グリコシドヒドロラーゼ酵素を使用する網膜細胞への遺伝子治療ベクターの送達の改善

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021568543A Pending JP2022533645A (ja) 2019-05-17 2020-04-15 グリコシドヒドロラーゼ酵素を使用する網膜細胞への遺伝子治療ベクターの送達の改善

Country Status (10)

Country Link
US (2) US20220226507A1 (cg-RX-API-DMAC7.html)
EP (2) EP3969059A1 (cg-RX-API-DMAC7.html)
JP (2) JP7707081B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220009427A (cg-RX-API-DMAC7.html)
CN (1) CN114126667A (cg-RX-API-DMAC7.html)
AR (1) AR118696A1 (cg-RX-API-DMAC7.html)
AU (2) AU2020278960A1 (cg-RX-API-DMAC7.html)
CA (2) CA3141020A1 (cg-RX-API-DMAC7.html)
TW (1) TW202110486A (cg-RX-API-DMAC7.html)
WO (2) WO2020236351A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020154535A1 (en) 2019-01-23 2020-07-30 University Of Florida Research Foundation, Incorporated Highly efficient transduction and lateral spread in the retina by a novel aav virus enhanced by rational design
US12019249B2 (en) * 2019-12-25 2024-06-25 Lumus Ltd. Optical systems and methods for eye tracking based on redirecting light from eye using an optical arrangement associated with a light-guide optical element
CN114516901B (zh) * 2022-03-11 2023-01-17 上海勉亦生物科技有限公司 一种神经系统高亲和性的aav载体及其应用
CN115323001B (zh) * 2022-07-28 2024-11-26 深圳先进技术研究院 一种靶向视网膜的基因递送系统及其应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
EP0733103B1 (en) 1993-11-09 2004-03-03 Targeted Genetics Corporation Generation of high titers of recombinant aav vectors
DE69433922T2 (de) 1993-11-09 2005-07-28 Medical College Of Ohio, Toledo Stabile zellinie, die in der lage ist, das replikationsgen des adenoassoziertenvirus zu exprimieren
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
WO1996017947A1 (en) 1994-12-06 1996-06-13 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant aav vectors
FR2737730B1 (fr) 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
JPH11511326A (ja) 1995-08-30 1999-10-05 ジエンザイム コーポレイション アデノウィルスおよびaavの精製
JPH11514853A (ja) 1995-09-08 1999-12-21 ジエンザイム コーポレイション 遺伝子治療のための改良されたaavベクター
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
EP1696036B1 (en) 1996-09-06 2010-04-21 The Trustees of The University of Pennsylvania Use of recombinant adeno-associated virus in the manufacture of a medicament for gene therapy via muscle cells
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
CA2995542A1 (en) 1997-09-05 1999-03-11 Genzyme Corporation Methods for generating high titer helper-free preparations of recombinant aav vectors
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
JP2004514407A (ja) 2000-04-28 2004-05-20 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 異種キャプシド中にシュードタイピングされたaav5キャプシドおよびaav5ベクターを含む組換えaavベクター
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US9233131B2 (en) 2003-06-30 2016-01-12 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
WO2012109214A1 (en) * 2011-02-07 2012-08-16 The University Of North Carolina At Chapel Hill Targeted transduction of aav vectors
CN103502458B (zh) * 2011-02-17 2016-11-16 宾夕法尼亚大学托管会 用于改变组织特异性和改善aav9-介导的基因转移的组合物和方法
US9434928B2 (en) 2011-11-23 2016-09-06 Nationwide Children's Hospital, Inc. Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
DE102012007232B4 (de) 2012-04-07 2014-03-13 Susanne Weller Verfahren zur Herstellung von rotierenden elektrischen Maschinen
CA2880653C (en) 2012-08-01 2022-05-17 Nationwide Children's Hospital Intrathecal delivery of recombinant adeno-associated virus 9
AU2014243925B2 (en) * 2013-03-14 2018-12-06 Wayne State University Method of enhancing delivery of therapeutic compounds to the eye
JP2015092462A (ja) 2013-09-30 2015-05-14 Tdk株式会社 正極及びそれを用いたリチウムイオン二次電池
WO2015126972A1 (en) * 2014-02-21 2015-08-27 University Of Florida Research Foundation, Inc. Methods and compositions for gene delivery to on bipolar cells
GB201403260D0 (en) * 2014-02-25 2014-04-09 Univ Manchester Treatment of retinal degeneration using gene therapy
WO2015141521A1 (ja) 2014-03-21 2015-09-24 株式会社日立国際電気 基板処理装置、半導体装置の製造方法及び記録媒体
LT3137497T (lt) * 2014-05-02 2021-07-26 Genzyme Corporation Aav vektoriai, skirti tinklainės ir cns genų terapijai
JP6197169B2 (ja) 2014-09-29 2017-09-20 東芝メモリ株式会社 半導体装置の製造方法
JP6754361B2 (ja) 2014-12-16 2020-09-09 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ 若年型バッテン病のための遺伝子療法
JP6684343B2 (ja) * 2015-05-21 2020-04-22 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ニューロン生存因子の相乗組み合わせ及びその使用
EP4134375A1 (en) 2015-07-30 2023-02-15 Massachusetts Eye & Ear Infirmary Ancestral adeno associated virus sequences and uses thereof
AU2016341428B2 (en) 2015-10-23 2021-12-02 University Of Iowa Research Foundation Methods for treating neurodegenerative diseases using gene therapy to delay disease onset and progression while providing cognitive protection
JP2019517274A (ja) 2016-06-13 2019-06-24 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルThe University Of North Carolina At Chapel Hill 最適化されたcln1遺伝子および発現カセットおよびそれらの使用
EP3516046B1 (en) * 2016-09-22 2022-07-13 Sorbonne Université Optogenetically transformed photoreceptor precursor cells for the use in the treatment of retinal degenerative diseases
MX2020003945A (es) * 2017-10-18 2020-11-09 Regenxbio Inc Tratamiento de enfermedades oculares y cancer de colon metastasico con vegf-trap humano modificado post-traduccionalmente .

Similar Documents

Publication Publication Date Title
Bordet et al. Ocular gene therapies in clinical practice: viral vectors and nonviral alternatives
JP2023545722A5 (cg-RX-API-DMAC7.html)
JP2021503914A5 (cg-RX-API-DMAC7.html)
JP2022141670A5 (cg-RX-API-DMAC7.html)
JP2022529775A5 (cg-RX-API-DMAC7.html)
RU2018142768A (ru) Варианты капсидов аденоассоциированного вируса и способы их применения
JP2018508519A5 (cg-RX-API-DMAC7.html)
EP4442698A1 (en) Modified aav capsid protein and use thereof
JP2022522776A5 (cg-RX-API-DMAC7.html)
JP2022533645A5 (cg-RX-API-DMAC7.html)
CN114126667A (zh) 使用糖苷水解酶的基因疗法载体向视网膜细胞的改进递送
US10533187B2 (en) Methods and compositions for restoration of cone function in BCM
EP4703475A1 (en) Nucleic acid encoding anti-vegf protein, polynucleotide expression cassette and recombinant adeno-associated virus
EP4707397A1 (en) Promoter for gene expression in retinal cells, and vector system comprising same
US20230338582A1 (en) Methods of Treating Human X-Linked Retinoschisis Using Gene Therapy
WO2023169115A1 (zh) 一种神经系统高亲和性的aav载体及其应用
JP7624727B2 (ja) 合理的設計により増強された新規なaavウイルスによる網膜における高効率の形質導入および側方への広がり
Kinnunen et al. Gene therapy in age related macular degeneration and hereditary macular disorders
EP2383286A1 (en) Methods and compositions for treatment of retinal degenerative diseases
JP2023523211A5 (cg-RX-API-DMAC7.html)
US20210308169A1 (en) Methods and compositions for treatment of retinal degenerative diseases
US20260131026A1 (en) Gene therapy for ocular disease
Gopinath et al. Gene therapy for retinal diseases
RU2861004C2 (ru) Модифицированный капсидный белок aav и его применение
CN115997012B (zh) Rpe65相关眼睛疾病和障碍的治疗